Elanco Animal Health Incorporated (NYSE:ELAN – Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday after the company announced weaker than expected quarterly earnings.

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

NEW YORK: The tech-heavy Nasdaq led Wall Street declines on Tuesday, hitting a six-week low after fresh economic data indicated a deterioration in consumer sentiment and investors braced for the ...

With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...

The prevalence of type 2 diabetes is rising globally, with a disproportionate impact on individuals in low-income and middle-income countries, where access to care and new therapies is often limited.

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

The data highlight the possibility of SGLT 1/2 inhibitors having protective effects beyond heart failure and diabetes.

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

Eli Lilly is lowering the cost barrier to its weight loss drug Zepbound.  For many consumers, their insurance denies them ...

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new available vial doses.

Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range ...